NASDAQ
20.01.26 | 21:59
1,310 US-Dollar
+11,97 % +0,140
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | 93 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim... ► Artikel lesen | |
| 08.12.25 | ALXO Presents Phase 2 Data Of Evorpacept In Frontline Indolent Non-Hodgkin Lymphoma At The ASH | 1 | RTTNews | ||
| 07.12.25 | ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | 175 | GlobeNewswire (Europe) | - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an... ► Artikel lesen | |
| 13.11.25 | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 4 | Investing.com | ||
| 07.11.25 | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| 07.11.25 | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| 07.11.25 | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 209 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen | |
| 07.11.25 | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Examining the Future: ALX Oncology Holdings' Earnings Outlook | 2 | Benzinga.com | ||
| 23.10.25 | Alx Oncology stock jumps after presenting preclinical ADC data at conference | 3 | Investing.com | ||
| 23.10.25 | Präklinische ADC-Daten beflügeln Aktie von Alx Oncology | 1 | Investing.com Deutsch | ||
| 23.10.25 | ALX Oncology stellt präklinische Daten für neuartigen EGFR-Krebswirkstoff vor | 7 | Investing.com Deutsch | ||
| 23.10.25 | ALX Oncology presents preclinical data for novel EGFR cancer drug | 1 | Investing.com | ||
| 03.10.25 | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10.25 | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 12.09.25 | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09.25 | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09.25 | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 299 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,898 | -1,70 % | Aixtron, Energiekontor, Evotec, HelloFresh, Hugo Boss, Renk, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 36,675 | -0,08 % | Biontech-Konkurrent Moderna im Aufwind: Ist das die Wende? | Die Aktien des Biontech-Rivalen Moderna setzen ihren Aufwärtstrend fort. Am Vormittag steigen sie um drei Prozent, nachdem sie gestern im US Handel zeitweise um 17 Prozent nach oben geschnellt waren.... ► Artikel lesen | |
| NOVAVAX | 6,974 | -0,27 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,600 | -0,89 % | CRISPR Therapeutics-Aktie: Wird die Geduld belohnt? | Die Aktie von CRISPR Therapeutics sorgt seit Jahren für starke Volatilität in beide Richtungen und stellt selbst erfahrene Anleger vor Geduldsproben. Zwischen Hoffnungen auf medizinische Durchbrüche... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,310 | 0,00 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,905 | -0,05 % | Cathie Wood's ARK adds to Intellia stock holdings on January 15 | ||
| DEFENCE THERAPEUTICS | 0,374 | +1,91 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| EDITAS MEDICINE | 1,725 | -0,17 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,870 | -0,40 % | BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition | ||
| SAREPTA THERAPEUTICS | 17,585 | -2,03 % | Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,040 | +1,49 % | PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research | ||
| EXELIXIS | 37,480 | +0,32 % | Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch | ||
| HALOZYME THERAPEUTICS | 59,72 | -0,67 % | Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty | ||
| NEUROCRINE BIOSCIENCES | 112,25 | -2,22 % | Neurocrine: Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy... ► Artikel lesen | |
| EXACT SCIENCES | 87,16 | -0,22 % | Assessing Exact Sciences: Insights From 16 Financial Analysts |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,310 Euro und damit +11,97 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.